Aimosti

Aimosti takes raw genome chip data (or a full whole-genome sequence, if you have one) and re-analyses it against current science, in the EU, under your control.

The report covers five areas: pharmacogenomics, carrier status, clinically actionable risk, everyday traits, and ancestry. The pharmacogenomics part is the one people come back for: how your body is likely to process 29 common medications, written up as a one-page hand-off you can bring to a doctor. The analysis differs from the usual raw-DNA tools in two ways. First, it reads your genome against Finnish population frequencies instead of a generic global average, and flags the founder conditions that are common in Finland. Second, it never imputes: if your chip didn't actually read a position, we say so rather than guessing, so you can see exactly what your data supports and what it doesn't.

Reports are one-time and yours to keep. An optional yearly subscription re-runs your genome as the science moves. You can try a free partial report first, and delete your data whenever you want. Aimosti is built by Aimosti Oy, a Finnish company, and your genome is stored and processed in the EU.